NAGE Niagen Bioscience, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Niagen Bioscience, Inc. (NAGE) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 4, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on March 19, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Niagen Bioscience, Inc. (NAGE) (SEC CIK 1386570), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Board increased share repurchase authorization to $20M from prior $10M, doubling buyback capacity to return capital to shareholders
- • $2.6M of stock repurchased through March 17, 2026, showing initial program uptake and market activity
Item 7.01: Regulation FD Disclosure
- • Corporate presentation published March 4, 2026, now available on company website and filed as Exhibit 99.2
- • Reg FD disclosure ensures all investors receive simultaneous access to material company information in the presentation
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 4, 2026
- • Actual figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item
Item 7.01: Regulation FD Disclosure
- • Niagen Bioscience (NAGE) divesting its analytical reference standards and services business unit
- • Asset sale signals strategic pivot — likely narrowing focus to core bioscience/NAD+ related operations
Item 8.01: Other Events
- • All-cash divestiture of analytical reference standards and services business to VHG Labs (LGC Group), closed Feb 24, 2026
- • Deal aligns with stated strategy to exit non-core assets and concentrate on NAD+ science platform, IP, and commercial growth
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Niagen Bioscience, Inc. (NAGE) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 19, 2026 | — | Analysis | — |
10-K | Mar 4, 2026 | Dec 31, 2025 | — | |
8-K | Mar 4, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Dec 22, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 7, 2025 | Mar 31, 2025 | — | |
10-K | Mar 4, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Mar 6, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Mar 8, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 10, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 14, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 3, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Mar 12, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest NAGE SEC filings in 2026?
Niagen Bioscience, Inc. (NAGE) has filed a 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on March 19, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did NAGE file its most recent 10-K annual report?
Niagen Bioscience, Inc. (NAGE) filed its most recent 10-K annual report on March 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view NAGE 10-Q quarterly reports?
Niagen Bioscience, Inc. (NAGE)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every NAGE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has NAGE filed recently?
Niagen Bioscience, Inc. (NAGE)'s most recent 8-K was filed on March 19, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find NAGE insider trading activity (Form 4)?
SignalX aggregates every NAGE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does NAGE file with the SEC?
Niagen Bioscience, Inc. (NAGE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NAGE filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Niagen Bioscience, Inc. (NAGE).
What is NAGE's SEC CIK number?
Niagen Bioscience, Inc. (NAGE)'s SEC CIK (Central Index Key) number is 1386570. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1386570 to look up all NAGE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find NAGE return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Niagen Bioscience, Inc. (NAGE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Niagen Bioscience, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 75+ filings.